Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 12,500 shares at $41.03 ($513K) on 2025-04-24, disclosed to the SEC on 2025-04-28.
Scheduled sale ($513k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.03 | 6,250 | $256K | 50.0% |
| 2 | $41.03 | 6,250 | $256K | 50.0% |
| Total | $41.03 avg | 12,500 | $513K | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |